The Lymphoma and Myeloma Program explores the causes, define the pathogenetic mechanisms, and improve the therapy of lymphoid neoplasms. Program members are: 1) experts in many of the most common lymphoid malignancies; 2) investigators with lymphoma and myeloma research programs spanning basic, translational and clinical areas; 3) dedicated clinical investigators; 4) hematopathologists with demonstrated expertise in lymphoid malignancies; and 5) computational biologists and biostatisticians with a focus on these diseases. Program Specific Aims are to: 1) Elucidate pathogenetic mechanisms underlying specific lymphoid neoplasms; 2) Develop novel therapeutic approaches to lymphoid malignancies; 3) Evaluate treatment outcomes and long-term complications in lymphoma and myeloma patients. The program has 74 members, representing five DF/HCC institutions and 12 academic departments. In 2014 peer-reviewed grant funding attributed to the Program was $10.1 million in total costs from the NCI and $8.2 million from other sponsors. During the current funding period, Lymphoma & Myeloma Program members published 1,271 cancer-relevant papers. Of these 30% were inter-institutional, 26% were intra-programmatic, and 44% were inter-programmatic collaborations between two or more DF/HCC members. Overall, when counted once, 27% of DF/HCC publications were inter-programmatic collaborations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-54
Application #
9614960
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
54
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Santana-Codina, Naiara; Roeth, Anjali A; Zhang, Yi et al. (2018) Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun 9:4945
Cox, Andrew G; Tsomides, Allison; Yimlamai, Dean et al. (2018) Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth. EMBO J 37:
Oxnard, Geoffrey R; Hu, Yuebi; Mileham, Kathryn F et al. (2018) Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol 4:1527-1534
Patil, Prasad; Parmigiani, Giovanni (2018) Training replicable predictors in multiple studies. Proc Natl Acad Sci U S A 115:2578-2583
Agoston, Agoston T; Pham, Thai H; Odze, Robert D et al. (2018) Columnar-Lined Esophagus Develops via Wound Repair in a Surgical Model of Reflux Esophagitis. Cell Mol Gastroenterol Hepatol 6:389-404
Barber, Lauren; Gerke, Travis; Markt, Sarah C et al. (2018) Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res 24:5910-5917
Kwee, Brian J; Budina, Erica; Najibi, Alexander J et al. (2018) CD4 T-cells regulate angiogenesis and myogenesis. Biomaterials 178:109-121
Madsen, Thomas; Braun, Danielle; Peng, Gang et al. (2018) Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data. Genet Epidemiol 42:528-538
Chen, Jingjing; Guccini, Ilaria; Di Mitri, Diletta et al. (2018) Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nat Genet 50:219-228
Li, Andrew G; Murphy, Elizabeth C; Culhane, Aedin C et al. (2018) BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation. Proc Natl Acad Sci U S A 115:E9600-E9609

Showing the most recent 10 out of 411 publications